Article

Therapeutic drug monitoring of lacosamide as add-on treatment in a neonate with therapy-resistant epilepsy due to SCN2A mutation

2025-02-25

Abstract excerpt

Lacosamide is registered for the treatment of (partial-onset) seizures in adults and children > 2 years of age, with a recommended maximum dose of 12 mg kg-1 in two doses. It is generally well tolerated. We present a case of a prematurely born neonate with refractory seizures despite multiple anti-epileptic drugs due to a denovo SCN2A mutation. Lacosamide was added, and serial plasma trough levels were measured to...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1f463e40-311f-5050-a55f-1b3b9c06d4ed
DOI: 10.22541/au.174048696.62941308/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Therapeutic drug monitoring of lacosamide as add-on treatment in a neonate with therapy-resistant epilepsy due to SCN2A mutationDOI 10.22541/au.174048696.62941308/v1Read

Lacosamide for SCN2A ‐related intractable neonatal and infantile seizuresSemantic proximity Read

Multi-centric Phase III, single-arm, open-label clinical study to assess clinical safety, tolerability, and efficacy of intravenous lacosamide in focal onset seizuresSemantic proximity Read

Impact of ABCC2 1249G>A and -24C>T Polymorphisms on Lacosamide Efficacy and Plasma Concentrations in Uygur Pediatric Patients With Epilepsy in China.Semantic proximity Read

Afebrile seizures in infants: Never forget magnesium!Semantic proximity Read

Impact of ABCB1 Polymorphisms on Lacosamide Serum Concentrations in Uygur Pediatric Patients With Epilepsy in China.Semantic proximity Read

Lacosamide Pharmacokinetics and Retention in Japanese Patients With Epilepsy: A Retrospective Study on the Influence of Age, Comedications, and Cytochrome P450 2C19 Polymorphism.Semantic proximity Read

Evidence-Based Selection of Antiepileptic Drugs During Pregnancy: A Narrative Review of Safety and EfficacySemantic proximity Read

Effects of CYP2C19 and CYP2C9 polymorphisms on the efficacy and plasma concentration of lacosamide in pediatric patients with epilepsy in China.Semantic proximity Read

Use of Sodium Channel Blockers in the Thr226Met Pathologic Variant of SCN1A: A Case Report.Semantic proximity Read

Effects of CYP2C19 genetic polymorphisms on the pharmacokinetics of lacosamide in Korean patients with epilepsySemantic proximity Read

Pharmacokinetic Changes and Seizure Outcomes in Pregnant Women Taking Second-Generation Antiepileptic DrugsSemantic proximity Read

Review or Updates on the clinical pharmacokinetics of levetiracetamSemantic proximity Read